Down-regulation of PTEN in breast cancer cells results in trastuzumab-resistance both in vitro and in vivo, but the use of PI3K inhibitors, such as LY294002 and Wortmannin, rescues PTEN loss-induced trastuzumab resistance [43]. Here, PTEN is linked to breast carcinoma.